Memorial Sloan Kettering Cancer Center, New York, New York.
Urology of St. Louis, St. Louis, Missouri.
J Urol. 2022 Jul;208(1):19-25. doi: 10.1097/JU.0000000000002758. Epub 2022 May 10.
The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after primary treatment. Please refer to Parts I and III for discussion of risk assessment, staging, and risk-based management (Part I), and principles of radiation and future directions (Part III).
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles.
The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding active surveillance, surgical management, and patient follow-up are detailed.
This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.
本文是三部分系列文章的第二部分,旨在介绍局限性前列腺癌:AUA/ASTRO 指南,内容涉及主动监测和手术的原则以及患者在主要治疗后的随访。请参考第一部分关于风险评估、分期和基于风险的管理以及第三部分关于放射治疗和未来方向的讨论。
为了为本指南提供信息,我们使用了系统评价方法。由独立方法学顾问进行。研究图书馆员在 Ovid MEDLINE、Cochrane 对照试验中心注册库和 Cochrane 系统评价数据库中进行了检索。方法学团队通过对之前 AUA 综述中包含的研究以及对相关文章的参考文献列表进行检索,对电子数据库的检索进行了补充。
临床局限性前列腺癌专家组制定了基于证据和共识的指南声明,以帮助临床医生管理临床局限性前列腺癌患者。详细介绍了主动监测、手术管理和患者随访的声明。
本指南旨在为治疗临床局限性前列腺癌患者的临床医生提供信息。继续开展研究并发表高质量的证据,将是进一步改善这些患者治疗的关键。